Literature DB >> 24819057

PET/CT imaging and the oligometastatic prostate cancer patient: an opportunity for a curative approach with high-dose radiotherapy?

Raymond Miralbell1, Franz Buchegger.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 24819057     DOI： 10.1007/s00259-014-2793-8

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  27 in total

1.  Comparison of PET/CT and PET/MRI hybrid systems using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience.

Authors:  A Afshar-Oromieh; U Haberkorn; H P Schlemmer; M Fenchel; M Eder; M Eisenhut; B A Hadaschik; A Kopp-Schneider; M Röthke
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-12-19       Impact factor: 9.236

2.  Fatigue in prostate cancer survivors treated with definitive radiotherapy and LHRH analogs.

Authors:  Anne E Kyrdalen; Alv A Dahl; Eivor Hernes; Einar Hem; Sophie D Fosså
Journal:  Prostate       Date:  2010-09-15       Impact factor: 4.104

3.  Androgen deprivation and high-dose radiotherapy for oligometastatic prostate cancer patients with less than five regional and/or distant metastases.

Authors:  Ulrike Schick; Sandra Jorcano; Philippe Nouet; Michel Rouzaud; Hansjoerg Vees; Thomas Zilli; Osman Ratib; Damien C Weber; Raymond Miralbell
Journal:  Acta Oncol       Date:  2013-04-02       Impact factor: 4.089

Review 4.  The role of PET/computed tomography scan in the management of prostate cancer.

Authors:  Maria Picchio; Elisabetta Giovannini; Cristina Messa
Journal:  Curr Opin Urol       Date:  2011-05       Impact factor: 2.309

5.  EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

Authors:  Nicolas Mottet; Joaquim Bellmunt; Michel Bolla; Steven Joniau; Malcolm Mason; Vsevolod Matveev; Hans-Peter Schmid; Theo Van der Kwast; Thomas Wiegel; Filiberto Zattoni; Axel Heidenreich
Journal:  Eur Urol       Date:  2011-01-25       Impact factor: 20.096

6.  Insurance and quality of life in men with prostate cancer: data from the Cancer of the Prostate Strategic Urological Research Endeavor.

Authors:  Natalia Sadetsky; Deborah P Lubeck; David J Pasta; David M Latini; Janeen DuChane; Peter R Carroll
Journal:  BJU Int       Date:  2008-03       Impact factor: 5.588

7.  First imaging results of an intraindividual comparison of (11)C-acetate and (18)F-fluorocholine PET/CT in patients with prostate cancer at early biochemical first or second relapse after prostatectomy or radiotherapy.

Authors:  Franz Buchegger; Valentina Garibotto; Thomas Zilli; Laurent Allainmat; Sandra Jorcano; Hansjörg Vees; Olivier Rager; Charles Steiner; Habib Zaidi; Yann Seimbille; Osman Ratib; Raymond Miralbell
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-10-09       Impact factor: 9.236

8.  Bilateral orchiectomy with or without flutamide for metastatic prostate cancer.

Authors:  M A Eisenberger; B A Blumenstein; E D Crawford; G Miller; D G McLeod; P J Loehrer; G Wilding; K Sears; D J Culkin; I M Thompson; A J Bueschen; B A Lowe
Journal:  N Engl J Med       Date:  1998-10-08       Impact factor: 91.245

9.  Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group.

Authors:  Fernando E C Calais da Silva; Aldo V Bono; Peter Whelan; Maurizio Brausi; Anton Marques Queimadelos; Jose A Portillo Martin; Ziya Kirkali; Fernando M V Calais da Silva; Chris Robertson
Journal:  Eur Urol       Date:  2009-02-21       Impact factor: 20.096

10.  Positron emission tomography (PET) imaging of prostate cancer with a gastrin releasing peptide receptor antagonist--from mice to men.

Authors:  Gesche Wieser; Rosalba Mansi; Anca L Grosu; Wolfgang Schultze-Seemann; Rebecca A Dumont-Walter; Philipp T Meyer; Helmut R Maecke; Jean Claude Reubi; Wolfgang A Weber
Journal:  Theranostics       Date:  2014-02-01       Impact factor: 11.556
View more
  4 in total

1.  Volumetric modulated arc therapy planning for primary prostate cancer with selective intraprostatic boost determined by 18F-choline PET/CT.

Authors:  Yu Kuang; Lili Wu; Emily Hirata; Kyle Miyazaki; Miles Sato; Sandi A Kwee
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-04-01       Impact factor: 7.038

Review 2.  Defining Oligometastatic Disease in the New Era of PSMA-PET Imaging for Primary Staging of Prostate Cancer.

Authors:  Samuel J Galgano; Andrew M McDonald; Janelle T West; Soroush Rais-Bahrami
Journal:  Cancers (Basel)       Date:  2022-07-06       Impact factor: 6.575

3.  OLIGOPELVIS - GETUG P07: a multicentre phase II trial of combined salvage radiotherapy and hormone therapy in oligometastatic pelvic node relapses of prostate cancer.

Authors:  Stephane Supiot; Emmanuel Rio; Valérie Pacteau; Marie-Hélène Mauboussin; Loïc Campion; François Pein
Journal:  BMC Cancer       Date:  2015-09-25       Impact factor: 4.430

Review 4.  Target Definition in Salvage Radiotherapy for Recurrent Prostate Cancer: The Role of Advanced Molecular Imaging.

Authors:  Gaël Amzalag; Olivier Rager; Claire Tabouret-Viaud; Michael Wissmeyer; Electra Sfakianaki; Thomas de Perrot; Osman Ratib; Raymond Miralbell; Giampiero Giovacchini; Valentina Garibotto; Thomas Zilli
Journal:  Front Oncol       Date:  2016-03-31       Impact factor: 6.244
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.